| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Kevin Hern OK01 | 4 | −$123.5K | Sold Sep 14, 26 | |
| Rob Bresnahan PA08 | 1 | 2 | +$16.5K | Sold May 15, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Sep 14, 26 | Kevin Hern OK01 | Joint | Sell | $15,001 - $50,000 | Sep 25, 26 (11d) | |
| Sep 8, 26 | Kevin Hern OK01 | Child | Sell | $1,001 - $15,000 | Sep 25, 26 (17d) | |
| Sep 3, 26 | Kevin Hern OK01 | Child | Sell | $1,001 - $15,000 | Sep 25, 26 (22d) | |
| Mar 16, 26 | Kevin Hern OK01 | Joint | Sell | $50,001 - $100,000 | Apr 3, 26 (18d) | |
| May 15, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | May 31, 25 (16d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Buy | $15,001 - $50,000 | May 8, 25 (30d) | |
| Feb 25, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | Mar 27, 25 (30d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Berkshire James GrantOfficer | Conversion of Exercise of derivative security at price 131.82 per share. | 5.4K | $709.32K |
| Sep 1, 2026 | Berkshire James GrantOfficer | Sale at price 261.33 per share. | 2.7K | $697.23K |
| Aug 2, 2026 | Staub Walter. Richard IiiOfficer | Sale at price 232.68 per share. | 5.5K | $1.28M |
| Jul 30, 2026 | Patel BhavikOfficer | Sale at price 235.27 per share. | 1.9K | $436.43K |
| Jul 28, 2026 | Bousbib Ari BChief Executive Officer | Conversion of Exercise of derivative security at price 78.21 per share. | 156.2K | $12.22M |
| Jul 28, 2026 | Bousbib Ari BChief Executive Officer | Sale at price 244.78 - 247.10 per share. | 106.3K | $26.09M |
| Jul 28, 2026 | Sherbet Eric MGeneral Counsel | Sale at price 249.16 per share. | 5K | $1.25M |
| Jul 28, 2026 | Cherofsky KeriannOfficer | Sale at price 245.21 per share. | 558 | $136.83K |
| Apr 22, 2026 | Danhakl John GDirector | Stock Award(Grant) at price 0.00 per share. | 1.6K | — |
| Apr 22, 2026 | Burt Carol JDirector | Stock Award(Grant) at price 0.00 per share. | 1.6K | — |
| Apr 22, 2026 | Leonard John MDirector | Stock Award(Grant) at price 0.00 per share. | 1.6K | — |
| Apr 22, 2026 | Goggins Colleen ADirector | Stock Award(Grant) at price 0.00 per share. | 1.6K | — |
| Feb 5, 2026 | Bousbib Ari BChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 57.2K | — |
| Feb 5, 2026 | Sherbet Eric MGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 6.8K | — |
| Feb 5, 2026 | Staub Walter. Richard IiiOfficer | Stock Award(Grant) at price 0.00 per share. | 2.7K | — |
| Feb 5, 2026 | Cherofsky KeriannOfficer | Stock Award(Grant) at price 0.00 per share. | 1.1K | — |
| Feb 5, 2026 | Patel BhavikOfficer | Stock Award(Grant) at price 0.00 per share. | 4.1K | — |
| Feb 5, 2026 | Berkshire James GrantOfficer | Stock Award(Grant) at price 0.00 per share. | 2.7K | — |
| Feb 5, 2026 | Haas BerndOfficer | Stock Award(Grant) at price 0.00 per share. | 8.3K | — |
| Feb 5, 2026 | Fedock Michael J.Officer | Stock Award(Grant) at price 0.00 per share. | 6.7K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.1 | -22.3 | -4.6 | -7.1 | 15.1 | 6.0 | 21.6 | 11.1 | 2.9 | -2.5 | +16.3% | ||
| 2025 | 2.5 | -6.2 | -6.6 | -12.0 | -9.5 | 12.3 | 17.9 | 2.7 | -0.5 | 14.0 | 6.3 | -2.0 | +14.7% |
| 2024 | -10.0 | 18.7 | 2.3 | -8.4 | -5.5 | -3.5 | 16.5 | 2.2 | -5.8 | -13.1 | -2.4 | -2.2 | −15.1% |
| 2023 | 12.0 | -9.1 | -4.6 | -5.4 | 4.6 | 14.1 | -0.4 | -0.5 | -11.6 | -8.1 | 18.4 | 8.1 | +12.9% |
| 2022 | -13.2 | -6.0 | 0.5 | -5.7 | -1.3 | 0.8 | 10.7 | -11.5 | -14.8 | 15.8 | 4.0 | -6.0 | −27.4% |
| 2021 | -0.8 | 8.4 | 0.2 | 21.5 | 2.3 | 0.9 | 2.2 | 4.9 | -7.8 | 9.1 | -0.9 | 8.9 | +57.5% |
| 2020 | 0.5 | -10.2 | -22.7 | 32.2 | 4.9 | -5.1 | 11.6 | 3.4 | -3.7 | -2.3 | 9.7 | 6.0 | +16.0% |
| 2019 | 11.1 | 8.6 | 2.7 | -3.4 | -2.2 | 18.4 | -1.1 | -2.5 | -3.7 | -3.3 | 1.1 | 5.8 | +33.0% |
| 2018 | 4.4 | -3.8 | -0.2 | -2.4 | 3.3 | 0.9 | 22.2 | 4.2 | 2.1 | -5.2 | 1.7 | -7.1 | +18.7% |
| 2017 | 3.2 | -1.4 | 4.1 | 4.7 | 2.6 | 3.5 | 1.2 | 6.1 | -1.0 | 13.7 | -5.6 | -4.0 | +28.7% |
| 2016 | -11.4 | 3.1 | 3.8 | 6.1 | -1.7 | -3.8 | 18.9 | -0.4 | 4.9 | -11.5 | 7.1 | -1.0 | +10.8% |
| 2015 | 2.8 | 7.4 | 3.1 | -1.6 | 5.8 | 4.2 | 5.7 | -2.9 | -6.6 | -8.5 | 6.8 | 1.0 | +16.6% |
| 2014 | 2.8 | 13.7 | -6.2 | -7.2 | 8.2 | 4.5 | 3.1 | 2.2 | -0.6 | 4.9 | -1.2 | 1.8 | +27.0% |
| 2013 | -3.4 | 5.4 | -3.5 | 3.7 | -6.4 | 2.9 | 7.3 | +5.2% |
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Buy / hold / sell counts